Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE

Chest

Volumn 140, Issue 2, 2011, Pages 366-373

  Warkentin, Theodore E ^a   Davidson, Bruce L ^b   Büller, Harry R ^c   Gallus, Alexander ^d   Gent, Michael ^a   Lensing, Anthonie W A ^c   Piovella, Franco ^e   Prins, Martin H ^f   Segers, Annelise E M ^c   Kelton, John G ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d FLINDERS MEDICAL CENTRE   (Australia)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; HEPARIN DEPENDENT ANTIBODY; LEPIRUDIN; THROMBOCYTE ACTIVATING FACTOR ANTIBODY; UNCLASSIFIED DRUG; WARFARIN;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INFERIOR CAVA VEIN THROMBOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; RISK ASSESSMENT; RISK REDUCTION; SECONDARY ANALYSIS; SIDE EFFECT; THROMBOCYTE COUNT; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 80051532509     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-1599     Document Type: Article

References (26)

1. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(suppl 6):454S-545S. (Pubitemid 351892971)
2. Geerts WH, Bergqvist D, Pineo GF, et alAmerican College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(suppl 6):381S-453S. (Pubitemid 351894916)
3. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355(8):809-817.
4. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330-1335.
5. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344(17):1286-1292. (Pubitemid 32372963)
6. Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med. 2005;146(6):341-346. (Pubitemid 41712020)
7. Greinacher A, Juhl D, Strobel U, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of anti-platelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost. 2007;5(8):1666-1673. (Pubitemid 47091409)
8. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67(1):27-30. (Pubitemid 16167006)
9. Savi P, Chong BH, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood. 2005;105(1):139-144. (Pubitemid 40053075)
10. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005;106(12):3791-3796. (Pubitemid 41739014)
11. Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost. 2005;93(5):999-1000. (Pubitemid 40691563)
12. Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost. 2008;99(1):208-214.
13. Büller HR, Davidson BL, Decousus H, et al Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349(18):1695-1702. (Pubitemid 37315006)
14. Büller HR, Davidson BL, Decousus H, et al Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004;140(11):867-873.
15. Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med. 2001;138(1):22-31. (Pubitemid 32589199)
16. Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol. 1996;95(1):161-167. (Pubitemid 26340246)
17. Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008;6(8):1304-1312. (Pubitemid 352016309)
18. Pouplard C, May MA, Regina S, Marchand M, Fusciardi J, Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol. 2005;128(6):837-841. (Pubitemid 40444878)
19. Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol. 2007;82(12):1037-1043. (Pubitemid 350209843)
20. Francis JL, Drexler A, Duncan MK, Walker JM, Hursting MJ, Levine RL. Heparin-platelet factor 4 antibodies in patients presenting to the ED with thrombosis. Am J Emerg Med. 2007;25(3):279-284. (Pubitemid 46356865)
21. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med. 2007;356(25):2653-2655.
22. Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia. Thromb Haemost. 2008;99(4):779-781. (Pubitemid 351694236)
23. Salem M, Elrefai S, Shrit MA, Warkentin TE. Fondaparinux-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke. Thromb Haemost. 2010;104(5):1071-1072.
24. Warkentin TE, Lim W. Can heparin-induced thrombocytopenia be associated with fondaparinux use? Reply to a rebuttal. J Thromb Haemost. 2008;6(7):1243-1246. (Pubitemid 351859141)
25. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score(4 Ts) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759-765.
26. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines(8th edition). Chest. 2008;133(suppl 6):340S-380S. (Pubitemid 351892970)